Scholarlink

<p>Taxane-induced peripheral neuropathy (TIPN) is one of the most common and clinically relevant toxicities of modern systemic cancer therapy. As survival rates improve, long-term treatment-related neurotoxicity is becoming increasingly important in oncologic care and survivorship. TIPN typically presents as a&#xa0;distal, symmetric, predominantly sensory, length-dependent polyneuropathy. Symptoms may arise during treatment, progress after therapy completion, and persist long term. In some patients, neuropathic pain develops and can markedly impair quality of life, functional independence, and adherence to therapy. Management options remain limited and largely focus on symptomatic treatment and, when necessary, dose adjustment while carefully balancing oncologic efficacy. Preventive pharmacologic strategies are lacking; therefore, early detection, continuous monitoring, and patient education are essential. This review summarizes current evidence on epidemiology, risk factors, pathophysiology, clinical presentation, diagnosis, prevention, treatment, and prognosis for patients with TIPN, aiming to provide clinically relevant guidance for daily practice and to support optimized survivorship care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Taxaninduzierte periphere Neuropathie in der gynäkologischen Onkologie

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月15日

查看全文
  • Lina Judit Schiestl,
  • Sophia Herzog,
  • Marcus Schmidt,
  • Roxana Schwab,
  • Annette Hasenburg,
  • Frank Birklein,
  • Livia Sophie Lang

摘要

Taxane-induced peripheral neuropathy (TIPN) is one of the most common and clinically relevant toxicities of modern systemic cancer therapy. As survival rates improve, long-term treatment-related neurotoxicity is becoming increasingly important in oncologic care and survivorship. TIPN typically presents as a distal, symmetric, predominantly sensory, length-dependent polyneuropathy. Symptoms may arise during treatment, progress after therapy completion, and persist long term. In some patients, neuropathic pain develops and can markedly impair quality of life, functional independence, and adherence to therapy. Management options remain limited and largely focus on symptomatic treatment and, when necessary, dose adjustment while carefully balancing oncologic efficacy. Preventive pharmacologic strategies are lacking; therefore, early detection, continuous monitoring, and patient education are essential. This review summarizes current evidence on epidemiology, risk factors, pathophysiology, clinical presentation, diagnosis, prevention, treatment, and prognosis for patients with TIPN, aiming to provide clinically relevant guidance for daily practice and to support optimized survivorship care.